EQL Pharma AB (publ) (STO:EQL)
Sweden · Delayed Price · Currency is SEK 26.30
+1.15 (4.57%)
At close: Aug 14, 2026
EQL Pharma AB Cash Flow Statement
Financials in millions SEK. Fiscal year is April - March.
Millions SEK. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | -14.04 | 12.54 | 43.12 | 22.71 | 30.92 | 31.55 |
Depreciation & Amortization | 19.57 | 19.57 | 10.1 | 7.66 | 7.43 | 2.76 |
Other Amortization | 2.56 | 2.56 | 2.42 | 0.62 | 1.14 | 0.78 |
Asset Writedown & Restructuring Costs | 0.97 | 0.97 | - | 0.47 | 7.84 | 6.73 |
Other Operating Activities | 1.13 | 5.67 | 11.23 | 0.07 | 8.13 | 7.2 |
Change in Accounts Receivable | 33.22 | 22.24 | -67.15 | -14.25 | -16.86 | -11.69 |
Change in Inventory | -22.12 | -21.5 | -73.41 | -40.26 | -23.69 | 0.68 |
Change in Other Net Operating Assets | -0.01 | -13.68 | 49.04 | 11.54 | 12.72 | 3.83 |
Operating Cash Flow | 21.27 | 28.36 | -24.65 | -11.44 | 27.62 | 41.83 |
Operating Cash Flow Growth | - | - | - | - | -33.98% | -30.34% |
Investing Activities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -0.06 | -5.44 | -6.13 | -0.93 | -0.46 | -0.63 |
Sale of Property, Plant & Equipment | 0.7 | - | - | - | - | - |
Sale (Purchase) of Intangibles | -54.45 | -61.8 | -239.72 | -65.34 | -20.05 | -21.46 |
Other Investing Activities | -0 | - | -0 | - | -0 | - |
Investing Cash Flow | -53.81 | -67.24 | -245.84 | -66.26 | -20.51 | -22.09 |
Financing Activities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Long-Term Debt Issued | - | 12.61 | 360.28 | 53.97 | - | 0.6 |
Long-Term Debt Repaid | - | -2.86 | -28.05 | -0.49 | -4.07 | -6.58 |
Net Debt Issued (Repaid) | 4.04 | 9.76 | 332.23 | 53.48 | -4.07 | -5.98 |
Issuance of Common Stock | 33.48 | 33.48 | 0.19 | 0.27 | 0.19 | 0.86 |
Other Financing Activities | 0 | 0 | - | - | 0 | - |
Financing Cash Flow | 37.53 | 43.24 | 332.43 | 53.74 | -3.88 | -5.12 |
Net Cash Flow
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Miscellaneous Cash Flow Adjustments | - | - | - | -0 | - | - |
Net Cash Flow | 4.99 | 4.36 | 61.93 | -23.96 | 3.23 | 14.62 |
Free Cash Flow
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 21.22 | 22.92 | -30.78 | -12.36 | 27.16 | 41.2 |
Free Cash Flow Growth | - | - | - | - | -34.08% | -30.92% |
Free Cash Flow Margin | 4.91% | 5.30% | -8.24% | -4.68% | 10.45% | 10.05% |
Free Cash Flow Per Share | 0.72 | 0.76 | -1.03 | -0.41 | 0.92 | 1.42 |
Levered Free Cash Flow | -29.75 | -41.69 | -291.55 | -89.53 | -9.9 | 1.84 |
Unlevered Free Cash Flow | -13.63 | -25.2 | -283.84 | -85.95 | -8.42 | 3.64 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | 29.88 | 30.48 | 13.02 | 4.01 | 2.29 | 2.78 |
Change in Working Capital | 11.1 | -12.94 | -91.52 | -42.96 | -27.83 | -7.18 |